

Å-zlem TÅ¼reci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2693051/publications.pdf>

Version: 2024-02-01

118
papers

36,707
citations

26630

56
h-index

20961

115
g-index

128
all docs

128
docs citations

128
times ranked

40608
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. <i>New England Journal of Medicine</i> , 2022, 386, 35-46.	27.0	431
2	Identification of neoantigens for individualized therapeutic cancer vaccines. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 261-282.	46.4	173
3	Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. <i>Science</i> , 2022, 375, 678-680.	12.6	303
4	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	4.1	117
5	Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2022, 386, 1910-1921.	27.0	215
6	Clinical development and approval of COVID-19 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 609-619.	4.4	26
7	Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. <i>Vaccine</i> , 2022, 40, 1483-1492.	3.8	32
8	Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1975-1988.	4.2	11
9	Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. <i>Science Immunology</i> , 2022, 7, .	11.9	144
10	Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial. <i>Advances in Therapy</i> , 2022, 39, 3789-3798.	2.9	3
11	A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. <i>Science</i> , 2021, 371, 145-153.	12.6	253
12	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. <i>Nature</i> , 2021, 592, 283-289.	27.8	494
13	Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+gastroesophageal adenocarcinoma. <i>Gastric Cancer</i> , 2021, 24, 721-730.	5.3	23
14	Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. <i>Science</i> , 2021, 371, 1152-1153.	12.6	485
15	Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. <i>Nature Medicine</i> , 2021, 27, 1062-1070.	30.7	114
16	mRNA therapeutics in cancer immunotherapy. <i>Molecular Cancer</i> , 2021, 20, 69.	19.2	168
17	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. <i>Nature</i> , 2021, 595, 572-577.	27.8	583
18	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. <i>New England Journal of Medicine</i> , 2021, 385, 239-250.	27.0	709

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. <i>New England Journal of Medicine</i> , 2021, 385, 1627-1629.	27.0	346
20	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. <i>New England Journal of Medicine</i> , 2021, 385, 1761-1773.	27.0	1,090
21	A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. <i>Nature Communications</i> , 2021, 12, 7105.	12.8	22
22	A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity. <i>Molecular Therapy</i> , 2020, 28, 119-128.	8.2	99
23	An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. <i>Science</i> , 2020, 367, 446-453.	12.6	286
24	COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. <i>Nature</i> , 2020, 586, 594-599.	27.8	1,520
25	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. <i>New England Journal of Medicine</i> , 2020, 383, 2439-2450.	27.0	2,107
26	PhaseÄ/II study of COVID-19 RNA vaccine BNT162b1 in adults. <i>Nature</i> , 2020, 586, 589-593.	27.8	1,197
27	A liposomal RNA vaccine inducing neoantigen-specific CD4 ⁺ T cells augments the antitumor activity of local radiotherapy in mice. <i>Oncolmmunology</i> , 2020, 9, 1771925.	4.6	32
28	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. <i>Nature</i> , 2020, 585, 107-112.	27.8	526
29	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, 2603-2615.	27.0	11,472
30	Dexamethasone premedication suppresses vaccine-induced immune responses against cancer. <i>Oncolmmunology</i> , 2020, 9, 1758004.	4.6	17
31	Personalized Neo-Epitope Vaccines for Cancer Treatment. <i>Recent Results in Cancer Research</i> , 2020, 214, 153-167.	1.8	9
32	PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation. <i>Oncotarget</i> , 2020, 11, 1862-1875.	1.8	7
33	HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. <i>Oncolmmunology</i> , 2019, 8, e1629259.	4.6	58
34	Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines. <i>Annual Review of Medicine</i> , 2019, 70, 395-407.	12.2	54
35	Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 870-876.	1.3	64
36	Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response. <i>Oncolmmunology</i> , 2019, 8, e1601480.	4.6	18

#	ARTICLE	IF	CITATIONS
37	A non-functional neopeptide specific CD8 ⁺ T-cell response induced by tumor derived antigen exposure <i>in vivo</i> . <i>Oncolmunology</i> , 2019, 8, 1553478.	4.6	16
38	Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening. <i>Molecular Therapy</i> , 2019, 27, 824-836.	8.2	191
39	Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide. <i>Journal of Nanobiotechnology</i> , 2018, 16, 39.	9.1	23
40	Personalized vaccines for cancer immunotherapy. <i>Science</i> , 2018, 359, 1355-1360.	12.6	697
41	A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. <i>European Journal of Cancer</i> , 2018, 100, 17-26.	2.8	85
42	Challenges towards the realization of individualized cancer vaccines. <i>Nature Biomedical Engineering</i> , 2018, 2, 566-569.	22.5	40
43	Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. <i>Nature Medicine</i> , 2017, 23, 815-817.	30.7	182
44	The European Regulatory Environment of RNA-Based Vaccines. <i>Methods in Molecular Biology</i> , 2017, 1499, 203-222.	0.9	22
45	Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome. <i>Methods in Molecular Biology</i> , 2017, 1499, 223-236.	0.9	9
46	Improvement of <i>In Vivo</i> Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins. <i>Human Gene Therapy</i> , 2017, 28, 1138-1146.	2.7	43
47	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. <i>Nature</i> , 2017, 547, 222-226.	27.8	1,806
48	Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity. <i>Journal of Immunology Research</i> , 2016, 2016, 1-13.	2.2	7
49	FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines. <i>Methods in Molecular Biology</i> , 2016, 1428, 163-175.	0.9	9
50	Targeting the Heterogeneity of Cancer with Individualized Neopeptide Vaccines. <i>Clinical Cancer Research</i> , 2016, 22, 1885-1896.	7.0	128
51	Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1075-1083.	4.2	59
52	The Human Vaccines Project: A roadmap for cancer vaccine development. <i>Science Translational Medicine</i> , 2016, 8, 334ps9.	12.4	162
53	Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. <i>Nature</i> , 2016, 534, 396-401.	27.8	1,243
54	Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6. <i>Oncolmunology</i> , 2016, 5, e1091555.	4.6	39

#	ARTICLE	IF	CITATIONS
55	Mutanome directed cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2016, 39, 14-22.	5.5	55
56	Chromatin Immunoprecipitation Assay to Identify Genomic Binding Sites of Regulatory Factors. <i>Methods in Molecular Biology</i> , 2016, 1366, 53-65.	0.9	3
57	CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer. <i>Oncotarget</i> , 2015, 6, 25356-25367.	1.8	40
58	Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. <i>Journal of Immunology Research</i> , 2015, 2015, 1-6.	2.2	27
59	Mutant MHC class II epitopes drive therapeutic immune responses to cancer. <i>Nature</i> , 2015, 520, 692-696.	27.8	1,030
60	Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies. <i>Oncotarget</i> , 2015, 4, e1005523.	4.6	2
61	Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion. <i>Human Gene Therapy</i> , 2015, 26, 751-766.	2.7	61
62	Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. <i>BMC Genomics</i> , 2014, 15, 190.	2.8	334
63	Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2014, 135, 2206-2214.	5.1	82
64	Peptide microarrays enable rapid mimotope optimization for pharmacokinetic analysis of the novel therapeutic antibody IMAB362. <i>Biotechnology Journal</i> , 2014, 9, 545-554.	3.5	6
65	Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. <i>International Journal of Cancer</i> , 2014, 134, 731-739.	5.1	67
66	mRNA-based therapeutics – developing a new class of drugs. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 759-780.	46.4	1,501
67	Functional TCR Retrieval from Single Antigen-Specific Human T Cells Reveals Multiple Novel Epitopes. <i>Cancer Immunology Research</i> , 2014, 2, 1230-1244.	3.4	35
68	Mutated tumor alleles are expressed according to their DNA frequency. <i>Scientific Reports</i> , 2014, 4, 4743.	3.3	40
69	Antigen Identification Using SEREX. <i>Methods in Molecular Biology</i> , 2013, 1061, 59-77.	0.9	6
70	NCOA3 is a selective co-activator of estrogen receptor β -mediated transactivation of PLAC1 in MCF-7 breast cancer cells. <i>BMC Cancer</i> , 2013, 13, 570.	2.6	21
71	Antitumor Vaccination with Synthetic mRNA: Strategies for In Vitro and In Vivo Preclinical Studies. <i>Methods in Molecular Biology</i> , 2013, 969, 235-246.	0.9	17
72	mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA. <i>Cancer Immunology Research</i> , 2013, 1, 386-392.	3.4	37

#	ARTICLE	IF	CITATIONS
73	Confidence-based Somatic Mutation Evaluation and Prioritization. <i>PLoS Computational Biology</i> , 2012, 8, e1002714.	3.2	30
74	Exploiting the Mutanome for Tumor Vaccination. <i>Cancer Research</i> , 2012, 72, 1081-1091.	0.9	706
75	mRNA as a Versatile Tool for Exogenous Protein Expression. <i>Current Gene Therapy</i> , 2012, 12, 347-361.	2.0	57
76	Targeting the tumor mutanome for personalized vaccination therapy. <i>Oncolmmunology</i> , 2012, 1, 768-769.	4.6	55
77	HLA typing from RNA-Seq sequence reads. <i>Genome Medicine</i> , 2012, 4, 102.	8.2	204
78	Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. <i>Gene</i> , 2011, 481, 83-92.	2.2	63
79	FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines. <i>Cancer Research</i> , 2011, 71, 6132-6142.	0.9	70
80	Tumor vaccination using messenger RNA: prospects of a future therapy. <i>Current Opinion in Immunology</i> , 2011, 23, 399-406.	5.5	114
81	Highly Specific Auto-Antibodies against Claudin-18 Isoform 2 Induced by a Chimeric HBcAg Virus-Like Particle Vaccine Kill Tumor Cells and Inhibit the Growth of Lung Metastases. <i>Cancer Research</i> , 2011, 71, 516-527.	0.9	45
82	Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics. <i>RNA Biology</i> , 2011, 8, 35-43.	3.1	32
83	Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity. <i>Cancer Research</i> , 2010, 70, 9031-9040.	0.9	253
84	Selective Activation of Trophoblast-specific PLAC1 in Breast Cancer by CCAAT/Enhancer-binding Protein β 2 (C/EBP β 2) Isoform 2. <i>Journal of Biological Chemistry</i> , 2009, 284, 28607-28615.	3.4	30
85	Selective activation of tumor growth-promoting Ca ²⁺ channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2. <i>Molecular Cancer</i> , 2009, 8, 77.	19.2	21
86	In silico strategy for detection of target candidates for antibody therapy of solid tumors. <i>Gene</i> , 2008, 414, 76-84.	2.2	2
87	MS4A12 Is a Colon-Selective Store-Operated Calcium Channel Promoting Malignant Cell Processes. <i>Cancer Research</i> , 2008, 68, 3458-3466.	0.9	58
88	Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals. <i>Journal of Immunology</i> , 2008, 180, 309-318.	0.8	141
89	Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development. <i>Clinical Cancer Research</i> , 2008, 14, 7624-7634.	7.0	247
90	A Placenta-Specific Gene Ectopically Activated in Many Human Cancers Is Essentially Involved in Malignant Cell Processes. <i>Cancer Research</i> , 2007, 67, 9528-9534.	0.9	82

#	ARTICLE	IF	CITATIONS
91	Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1577-1587.	4.2	46
92	Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. <i>Cancer Letters</i> , 2006, 236, 64-71.	7.2	71
93	Identification of new claudin family members by a novel PSI-BLAST based approach with enhanced specificity. <i>Proteins: Structure, Function and Bioinformatics</i> , 2006, 65, 808-815.	2.6	19
94	Expression profiling of autoimmune regulator AIRE mRNA in a comprehensive set of human normal and neoplastic tissues. <i>Immunology Letters</i> , 2006, 106, 172-179.	2.5	31
95	Rapid molecular dissection of viral and bacterial immunomes. <i>European Journal of Immunology</i> , 2006, 36, 1049-1057.	2.9	11
96	Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2006, 118, 2522-2528.	5.1	47
97	The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes. <i>Human Molecular Genetics</i> , 2006, 15, 2392-2399.	2.9	24
98	Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. <i>Blood</i> , 2006, 108, 4009-4017.	1.4	457
99	Identification of Tumor-Associated Autoantigens With SEREX. , 2005, 109, 137-154.		24
100	Molecular Characterization of Virus-induced Autoantibody Responses. <i>Journal of Experimental Medicine</i> , 2004, 200, 637-646.	8.5	40
101	Frequent Nonrandom Activation of Germ-Line Genes in Human Cancer. <i>Cancer Research</i> , 2004, 64, 5988-5993.	0.9	45
102	CrELISA: a fast and robust enzyme-linked immunosorbent assay bypassing the need for purification of recombinant protein. <i>Journal of Immunological Methods</i> , 2004, 289, 191-199.	1.4	14
103	SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity. <i>Journal of Immunological Methods</i> , 2003, 283, 261-267.	1.4	23
104	Expression of serologically identified tumor antigens in acute leukemias. <i>Leukemia Research</i> , 2003, 27, 655-660.	0.8	37
105	Cascades of transcriptional induction during dendritic cell maturation revealed by genome-wide expression analysis. <i>FASEB Journal</i> , 2003, 17, 836-847.	0.5	79
106	A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing. <i>Oncogene</i> , 2002, 21, 3879-3888.	5.9	43
107	Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. <i>Cancer Research</i> , 2002, 62, 6750-5.	0.9	84
108	Recognition of human tumors: SEREX expression cloning to identify tumour antigens. , 2001, , 45-57.		4

#	ARTICLE	IF	CITATIONS
109	Expression of the Membrane-associated Carbonic Anhydrase Isozyme XII in the Human Kidney and Renal Tumors. <i>Journal of Histochemistry and Cytochemistry</i> , 2000, 48, 1601-1608.	2.5	113
110	Expression of a Novel Transmembrane Carbonic Anhydrase Isozyme XII in Normal Human Gut and Colorectal Tumors. <i>American Journal of Pathology</i> , 2000, 156, 577-584.	3.8	137
111	Characterization of DP103, a Novel DEAD Box Protein That Binds to the Epstein-Barr Virus Nuclear Proteins EBNA2 and EBNA3C. <i>Journal of Biological Chemistry</i> , 1999, 274, 19136-19144.	3.4	93
112	Characterization of human colon cancer antigens recognized by autologous antibodies. <i>International Journal of Cancer</i> , 1998, 76, 652-658.	5.1	281
113	Expression of SSX genes in human tumors. , 1998, 77, 19-23.		143
114	Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies. , 1998, 78, 387-389.		99
115	Identification of Human Tumor Antigens Using the B-Cell Repertoire. , 1998, , 185-198.		1
116	Molecular Definition of a Novel Human Galectin Which Is Immunogenic in Patients with Hodgkin's Disease. <i>Journal of Biological Chemistry</i> , 1997, 272, 6416-6422.	3.4	223
117	Serological identification of human tumor antigens. <i>Current Opinion in Immunology</i> , 1997, 9, 709-716.	5.5	292
118	SSX: A multigene family with several members transcribed in normal testis and human cancer. <i>International Journal of Cancer</i> , 1997, 72, 965-971.	5.1	190